Blockade of angiotensin signaling improves myocardial function in hypercholesterolemia independent of changes in eicosanoid release

Cardiovascular Drugs and Therapy

Volumn 14, Issue 3, 2000, Pages 317-327

  Schwemmer, Michael ^a   Sommer, Olaf ^a   Bassenge, Eberhard ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Angiotensin signaling; Eicosanoids; Hypercholesterolemia; Myocardial function; Oxidant stress

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ICOSANOID; LOSARTAN; PROSTACYCLIN; THROMBOXANE; XANTHINE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL DIET; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; ENZYME IMMUNOASSAY; GUINEA PIG; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE PRESSURE; HEART PERFORMANCE; HYPERCHOLESTEROLEMIA; ICOSANOID METABOLISM; ISOLATED HEART; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SPECTROPHOTOMETRY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINS; ANIMALS; CHOLESTEROL, DIETARY; CORONARY CIRCULATION; EICOSANOIDS; GUINEA PIGS; HEART; HYPERCHOLESTEROLEMIA; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; PROTEINS; RECEPTORS, ANGIOTENSIN; SIGNAL TRANSDUCTION;

EID: 0033948202     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007838809551     Document Type: Article

References (77)

1. 1. Yang BC, Phillips MI, Mohuczy D, et al. Increased angiotensin II type 1 receptor expression in hypercholesterolemic atherosclerosis in rabbits. Arterioscl Thromb Vasc Biol 1998;18:1433-1439.
2. 2. Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 1998;83:952-959.
3. 3. Nickenig G, Baumer AT, Grohe C, et al. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation 1998;97:2197-2201.
4. 4. Shibata H, Suzuki H, Maruyama T, Saruta T. Gene expression of angiotensin II receptor in blood cells of Cushing's syndrome. Hypertension 1995;26:1003-1010.
5. 5. Makarious M, Pawlak M, Campbell LV, et al. The platelet angiotensin II receptor in type I diabetes: Studies in patients with and without nephropathy. Eur J Clin Invest 1993;23:517-521.
6. 6. Miyazaki H, Shibata T, Fujii N. [Intracellular signaling pathways of angiotensin II receptor type 1 involved in the development of cardiovascular diseases] [in Japanese]. Nippon Rinsho - Jpn J Clin Med 1998;56:1906-1911.
7. 7. Hernandez A, Barberi L, Ballerio R, et al. Delapril slows the progression of atherosclerosis and maintains endothelial function in cholesterol-fed rabbits. Atherosclerosis 1998;137:71-76.
8. 8. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-1148.
9. 9. Nickenig G, Jung O, Strehlow K, et al. Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression. Am J Physiol 1997;272:H2701-H2707.
10. 10. Nickenig G, Bohm M. Regulation of the angiotensin AT1 receptor expression by hypercholesterolemia. Eur J Med Res 1997;2:285-289.
11. 11. Nickenig G, Bohm M. [Significance of the angiotensin-II receptor AT1 in the pathogenesis of arterial hypertension and arteriosclerosis] [in German]. D Med Wochenschr 1997;122:1009-1013.
12. 1-adrenergic plus angiotensin receptor blockade reduces atherosclerosis in apolipoprotein E-deficient mice. Hypertension 1998;32:1044-1048.
13. 13. de Zeeuw D, Gansevoort RT, de Jong PE. Losartan in patients with renal insufficiency. Can J Cardiol 1995; 11(Suppl. F):41F-44F.
14. 14. Tazawa S, Nakane T, Chiba S. Angiotensin II type 1 receptor blockade prevents up-regulation of angiotensin II type 1A receptors in rat injured artery. J Pharmacol Exp Ther 1999;288:898-904.
15. 15. Jacobsson LS, Persson K, Aberg G, Andersson RG, Karlberg BE, Olsson AG. Antiatherosclerotic effects of the angiotensin-converting enzyme inhibitors captopril and fosinopril in hypercholesterolemic minipigs. J Cardiovasc Pharmacol 1994;24:670-677.
16. 16. Kowala MC, Grove RI, Aberg G. Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids. Atherosclerosis 1994;108:61-72.
17. 17. Mira ML, Silva MM, Queiroz MJ, Manso CF. Angiotensin converting enzyme inhibitors as oxygen free radical scavengers. Free Radical Res Commun 1993;19:173-181.
18. 18. Sakemi T, Baba N, Yoshikawa Y. Angiotensin-converting enzyme inhibition attenuates hypercholesterolemia and glomerular injury in hyperlipidemic Imai rats. Nephron 1992;62:315-321.
19. 19. de Cavanagh EM, Inserra F, Ferder L, Romano L, Ercole L, Fraga CG. Superoxide dismutase and glutathione peroxidase activities are increased by enalapril and captopril in mouse liver. FEBS Lett 1995;361:22-24.
20. 20. Keidar S, Attias J, Smith J, Breslow JL, Hayek T. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Comm 1997;236:622-625.
21. 21. Tayeh MA, Scicli AG. Angiotensin II and bradykinin regulate the expression of P-selectin on the surface of endothelial cells in culture. Proc Assoc Am Phys 1998;110:412-421.
22. 22. Davies KJ. Oxidative stress: The paradox of aerobic life. Biochem Soc Symp 1995;61:1-31.
23. 23. Rattan V, Sultana C, Shen Y, Kalra VK. Oxidant stress-induced transendothelial migration of monocytes is linked to phosphorylation of PECAM-1. Am J Physiol 1997;273:E453-E461.
24. 24. Kaplowitz N, Fernandez-Checa JC, Kannan R, Garcia-Ruiz C, Ookhtens M, Yi JR. GSH transporters: Molecular characterization and role in GSH homeostasis. Biol Chem Hoppe-Seyle 1996;377:267-273.
25. 25. Kurose I, Wolf RE, Grisham MB, Granger DN. Hypercholesterolemia enhances oxidant production in mesenteric venules exposed to ischemia/reperfusion. Arterioscler Thromb Vasc Biol 1998;18:1583-1588.
26. 26. Davi G, Alessandrini P, Mezzetti A, et al. In vivo formation of 8-epi-prostaglandin F2 alpha is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997;17:3230-3235.
27. 27. Ma XL, Lopez BL, Liu GL, et al. Hypercholesterolemia impairs a detoxification mechanism against peroxynitrite and renders the vascular tissue more susceptible to oxidative injury. Circ Res 1997;80:894-901.
28. 28. Simon E, Paul JL, Atger V, Simon A, Moatti N. Erythrocyte antioxidant status in asymptomatic hypercholesterolemic men. Atherosclerosis 1998;138:375-381.
29. 29. Wilcox JN, Subramanian RR, Sundell CL, et al. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol 1997;17:2479-2488.
30. 30. Khan BV, Harrison DG, Olbrych MT, Alexander RW, Medford RM. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci USA 1996;93:9114-9119.
31. 31. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993;91:2546-2551.
32. 32. Harrison DG. Endothelial dysfunction in atherosclerosis. Basic Res Cardiol 1994;89(Suppl. 1):87-102.
33. 33. Kooy NW, Lewis SJ. The peroxynitrite product 3-nitro-L-tyrosine attenuates the hemodynamic responses to angiotensin II in vivo. Eur J Pharmacol 1996;315:165-170.
34. 34. Blann AD, Maxwell SR, Burrows G, Miller JP. Antioxidants, von Willebrand factor and endothelial cell injury in hypercholesterolaemia and vascular disease. Atherosclerosis 1995;116:191-198.
35. 35. Wohlfeil ER, Campbell WB. 25-Hydroxycholesterol enhances eicosanoid production in cultured bovine coronary artery endothelial cells by increasing prostaglandin G/H synthase-2. Biochim Biophys Acta 1997;1345:109-120.
36. 36. Davi G, Gresele P, Violi F, et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 1997;96:69-75.
37. 37. Weber AA, Hohlfeld T, Strobach H, Schrör K, Schrör K. Oral naftidrofuryl prevents platelet hyperreactivity ex vivo and inhibits functional desensitization to prostacyclin in hypercholesterolemic rabbits. J Cardiovasc Pharmacol 1993;21:332-338.
38. 38. Kaul S, Waack BJ, Padgett RC, Brooks RM, Heistad DD. Altered vascular responses to platelets from hypercholesterolemic humans. Circ Res 1993;72:737-743.
39. 39. Bailey JM, Makheja AN, Lee R, Simon TH. Systemic activation of 15-lipoxygenase in heart, lung, and vascular tissues by hypercholesterolemia: Relationship to lipoprotein oxidation and atherogenesis. Atherosclerosis 1995;113:247-258.
40. 40. Lynch SM, Gaziano JM, Frei B. Ascorbic acid and atherosclerotic cardiovascular disease. Sub-Cellular Biochem 1996;25:331-367.
41. 41. Sullivan MP, Cerda JJ, Robbins FL, Burgin CW, Beatty RJ. The gerbil, hamster, and guinea pig as rodent models for hyperlipidemia. Lab Animal Sc 1993;43:575-578.
42. 42. Fitzgerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984;310:1065-1068.
43. 43. Bergmeyer HU. Methods of Enzymatic Analysis, Vol. III. Enzymes 1: Oxidoreductases, Transferases, 3rd ed. Weinheim: Verlag Chemie, 1963.
44. 44. Asano K, Dutcher DL, Port JD, et al. Selective downregulation angiotensin II AT(1)-receptor subtype in failing human ventricular myocardium. Circulation 1997;96:4435.
45. 45. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with phenol reagent. J Biol Chem 1951;193:265-275.
46. 46. Galle J, Busse R, Bassenge E. Hypercholesterolemia and atherosclerosis change vascular reactivity in rabbits by different mechanisms. Arterioscl Thromb 1991;11:1712-1718.
47. 47. Cardillo C, Kilcoyne CM, Cannon RO, Quyyumi AA, Panza JA. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 1997;30:57-63.
48. 48. Mügge A, Brandes RP, Böger RH, et al. Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits. J Cardiovasc Pharmacol 1994;24:994-998.
49. 49. White CR, Darley-Usmar V, Berrington WR, et al. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci USA 1996;93:8745-8749.
50. 50. Janssen M, de Jong JW, Pasini E, Ferrari R. Myocardial xanthine oxidoreductase activity in hypertensive and hypercholesterolemic rats. Cardioscience 1993;4:25-29.
51. 51. Keane WF, Shapiro BE. Renal protective effects of angiotensin-converting enzyme inhibition. Am J Cardiol 1990;65:491-531.
52. 52. Bartosz M, Kedziora J, Bartosz G. Antioxidant and prooxidant properties of captopril and enalapril. Free Radical Biol Med 1997;23:729-735.
53. 53. Djordjevic VB, Pavlovic D, Pejovic M, Cvetkovic T, Lecic N, Deljanin-Ilic M. Changes of lipid peroxides and antioxidative factors levels in blood of patients treated with ACE inhibitors. Clin Nephr 1997;47:243-247.
54. 54. de Cavanagh EM, Fraga CG, Ferder L, Inserra F. Enalapril and captopril enhance antioxidant defenses in mouse tissues. Am J Physiol 1997;272:R514-R518.
55. 55. Haller H, Oeney T, Hauck U, Distler A, Philipp T. Increased intracellular free calcium and sensitivity to angiotensin II in platelets of preeclamptic women. Am J Hypertens 1989;2:238-243.
56. 56. Zhang Z, Blake DR, Stevens CR, et al. A reappraisal of xanthine dehydrogenase and oxidase in hypoxic reperfusion injury: The role of NADH as an electron donor. Free Radical Res 1998;28:151-164.
57. 57. Baur LH, Schipperheyn JJ, Baan J, et al. Influence of angiotensin converting enzyme inhibition on pump function and cardiac contractility in patients with chronic congestive heart failure. Br Heart J 1991;65:137-142.
58. 58. Nunez E, Hosoya K, Susic D, Frohlich ED. Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Hypertension 1997;29:519-524.
59. 59. Gohlke P, Linz W, Scholkens BA, Wiemer G, Unger T. Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats. Hypertension 1996;28:397-402.
60. 60. Werrmann JG, Cohen SM. Use of losartan to examine the role of the cardiac renin-angiotensin system in myocardial dysfunction during ischemia and reperfusion. J Cardiovasc Pharmacol 1996;27:177-182.
61. 61. Sudhir K, MacGregor JS, Gupta M, et al. Effect of selective angiotensin II receptor antagonism and angiotensin converting enzyme inhibition on the coronary vasculature in vivo: Intravascular two-dimensional and Doppler ultrasound studies. Circulation 1993;87:931-938.
62. 62. Kyriakidis M, Triposkiadis F, Dernellis J, et al. Effects of cardiac versus circulatory angiotensin-converting enzyme inhibition on left ventricular diastolic function and coronary blood flow in hypertrophic obstructive cardiomyopathy. Circulation 1998;97:1342-1347.
63. 63. Wagner OF, Christ G, Wojta J, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992;267:16066-16068.
64. 64. Vicaut E. Hypertension and the microcirculation: A brief overview of experimental studies. J Hypertens 1992;10(Suppl. 5):S59-S68.
65. 65. Dumoulin MJ, Adam A, Blais CJ, Lamontagne D. Metabolism of bradykinin by the rat coronary vascular bed. Cardiovasc Res 1998;38:229-236.
66. 66. Tio RA, Van Wijngaarden J, Scholtens E, van Gilst WH, de Langen CD, Wesseling H. The increase in coronary flow induced by converting enzyme inhibitors is prostacyclin independent. Prog Clin Biol Res 1989;301:435-439.
67. 67. Umemura K, Wada K, Suzuki Y, Nishiyama H, Nakashima M. Altered prostaglandin metabolism induced by angiotensin-converting enzyme inhibitors in bronchoalveolar lavage fluid of the guinea pig. Jpn J Pharmacol 1996;72:17-21.
68. 68. Harding P, Stonier C, Aber GM. Dose-dependent effects of angiotensin converting enzyme (ACE) inhibitors on glomerular prostanoid production by normotensive rats. Br J Pharmacol 1993;108:327-330.
69. 69. Catalioto RM, Porchia R, Renzetti AR, Criscuoli M, Subissi A, Giachetti A. Angiotensin II-induced responses in vascular smooth muscle cells: Inhibition by non-peptide receptor antagonists. Eur J Pharmacol 1995;280:285-292.
70. 70. Leung KH, Chang RS, Lotti VJ, et al. AT1 receptors mediate the release of prostaglandins in porcine smooth muscle cells and rat astrocytes. Am J Hypertens 1992;5:648-656.
71. 71. Sadoshima J, Izumo S. Signal transduction pathways of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro. Roles of phospholipid-derived second messengers. Circ Res 1993;73:424-438.
72. 2+-independent PLA2. Am J Physiol 1997;273:F554-F562.
73. 73. Mangat H, Peterson LN, Burns KD. Hypercalcemia stimulates expression of intrarenal phospholipase A2 and prostaglandin H synthase-2 in rats. Role of angiotensin II AT1 receptors. J Clin Invest 1997;100:1941-1950.
74. 74. Lokuta AJ, Cooper C, Gaa ST, Wang HE, Rogers TB. Angiotensin II stimulates the release of phospholipid-derived second messengers through multiple receptor subtypes in heart cells. J Biol Chem 1994;269:4832-4838.
75. 75. Boger RH, Bode-Böger SM, Brandes RP, et al. Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: Comparison with lovastatin. Circulation 1997;96:1282-1290.
76. 76. Simonet S, Porro dBJ, Descombes JJ, Mennecier P, Laubie M, Verbeuren TJ. Hypoxia causes an abnormal contractile response in the atherosclerotic rabbit aorta. Implication of reduced nitric oxide and cGMP production. Circ Res 1993;72:616-630.
77. 77. Weisbrod RM, Griswold MC, Du Y, Bolotina VM, Cohen RA. Reduced responsiveness of hypercholesterolemic rabbit aortic smooth muscle cells to nitric oxide. Art Thromb Vasc Biol 1997;17:394-402.